Last updated: February 20, 2026
What is NDC 46122-0695?
NDC 46122-0695 corresponds to Ozempic (semaglutide) injection 0.5 mg and 1 mg, developed by Novo Nordisk. It is a GLP-1 receptor agonist approved by the FDA in 2017 for type 2 diabetes management and subsequently for weight management.
Current Market Landscape
Market Size and Demand
- The global GLP-1 receptor agonist market was valued at approximately $4.1 billion in 2022.
- Projected to reach $12.3 billion by 2027, growing at a CAGR of roughly 23%.
- The growth is driven by expanding indications, especially obesity treatment, and increased adoption among diabetic patients.
Key Competitors
| Manufacturer |
Product Name |
Indications |
Market Share (2022) |
| Novo Nordisk |
Ozempic, Wegovy |
Diabetes, obesity |
65% |
| Eli Lilly |
Trulicity, Mounjaro |
Diabetes |
20% |
| AstraZeneca |
Bydureon, Byetta |
Diabetes |
10% |
| Others |
-- |
-- |
5% |
Ozempic holds the dominant position for diabetes, while Wegovy (another semaglutide formulation approved in 2021 for obesity) targets weight management.
Regulatory and Reimbursement Landscape
- Widely covered by insurance in the U.S.
- CMS and private payers offer favorable coverage, with co-pay assistance programs reducing patient barriers.
- International approvals vary; notable markets include Europe, Japan, and Canada, with growth potential as approvals expand.
Pricing Analysis
Current Pricing
- List Price (U.S.): Approximately $900–$1,000 per monthly injection (for 0.5 mg to 1 mg doses).
- Net Price: After rebates and discounts, estimated at $700–$800 per unit for payers.
Cost Comparison with Competitors
| Product |
Typical Monthly Cost |
Approval Year |
Key Indication |
| Ozempic (semaglutide) |
~$900 |
2017 |
Diabetes |
| Trulicity (dulaglutide) |
~$800–$900 |
2014 |
Diabetes |
| Mounjaro (tirzepatide) |
~$950–$1,200 |
2022 |
Diabetes |
| Wegovy (semaglutide) |
~$1,300 |
2021 |
Obesity |
Price Trends
- Steady premium relative to competitors due to higher efficacy data.
- Discounting prevalent among payers and via patient assistance programs.
- Potential for price increases as new indications and longer-term data emerge.
Future Market and Price Projections
Factors Influencing Price
- Regulatory approvals of higher-dose formulations for obesity.
- Increased competition from newer drugs with similar or superior efficacy.
- Patent life and potential biosimilar entry, expected beyond 2030.
- Payer negotiations and formulary decisions affect net prices.
Market Growth and Revenue Projections
| Year |
Estimated Revenue (USD billions) |
Growth Rate |
Key Drivers |
| 2023 |
$4.5 |
-- |
Continued adoption, price stability |
| 2024 |
$5.4 |
20% |
Expanded indications, awareness |
| 2025 |
$6.6 |
22% |
Market penetration, new dosing |
| 2026 |
$8.0 |
21% |
Competitive launches, policies |
| 2027 |
$12.3 |
53% |
Obesity market, new formulations |
Price Projections
- Monthly retail price: Expected to stay in the $900 range through 2025.
- Reimbursement-adjusted prices: Likely to decrease slightly due to payer negotiations.
- Long-term: Prices may increase marginally if new formulations dominate, with possible discounts diminishing.
Potential Impact of Biosimilars and Generics
- Patent exclusivity expected to expire post-2030.
- Biosimilar development streams are ongoing, with early-stage candidates.
- Entry of biosimilars could pressure list prices downward by approximately 20–30%.
Strategic Insights
- Key drivers for market share growth include expanding indications, especially obesity.
- Price sensitivity in value-based contracts with payers could influence net prices.
- Novo Nordisk's continued investment in marketing, reimbursement strategies, and novel formulations will shape long-term price stability.
Key Takeaways
- NDC 46122-0695 (Ozempic) dominates its therapeutic segment, with a significant market share.
- Pricing remains stable around $900–$1,000 per month, with discounts and rebates reducing net costs.
- Market growth is robust, driven by expanding indications and consumer awareness.
- Long-term price declines are likely after biosimilar entry, but peak revenues will persist until patent expiration.
- Competition from formulations like Wegovy and Mounjaro influences pricing strategies and market dynamics.
FAQs
1. Will the price of Ozempic increase or decrease over the next five years?
Prices are likely to stay stable initially, with minor increases driven by inflation and formulation updates. Significant decreases may occur upon biosimilar entry around 2030.
2. How does pricing of Ozempic compare internationally?
Pricing varies widely; European markets generally price lower due to healthcare policies and negotiation power, with U.S. prices remaining higher due to market dynamics.
3. Is the current market for Ozempic saturated?
No. The market is growing driven by new indications, including weight management, and expanding into international markets with unmet needs.
4. What factors could impact future pricing strategies?
Regulatory changes, patent expiries, competitive launches of biosimilars, and payer negotiations all influence pricing strategies.
5. How are reimbursement policies evolving for semaglutide products?
Payers increasingly favor value-based arrangements, impacting net prices and access. Coverage policies are tightening in some regions but expanding in others as evidence of efficacy grows.
References
- MarketWatch. (2022). Global GLP-1 receptor agonist market report.
- IQVIA. (2022). U.S. pharmaceutical pricing and trend analysis.
- FDA. (2017). Approval of Ozempic (semaglutide).
- EvaluatePharma. (2023). Pharmaceutical market forecasts.
[1] US Food and Drug Administration. (2017). Ozempic (semaglutide) prescribing information.
